Pediatrics · LP-003
Cetirizine Syrup
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-003Pediatrics
- Generic identity
- CetirizineSyrup
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-003
- Generic identity
- Cetirizine
- Presentation
- Syrup
- Catalogue strength
- 5 mg/5 mL
- Catalogue pack
- Bottle 60 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cetirizine.
- Dosage form: syrup.
- Catalogue concentration: 5 mg/5 mL.
- Catalogue pack: bottle 60 mL.
- Catalogue category: Pediatrics; category is navigation, not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Approved age range and indication for this exact product.
- Salt/base expression, excipients, flavouring, preservatives and whether shaking is required.
- Calibrated measuring-device specification and dosing instructions.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg/5 mL | Syrup | — | Bottle 60 mL | Age eligibility, formula/excipients and measuring instructions require the exact controlled label/specification. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cetirizine is an antihistamine used to relieve symptoms associated with allergy, including allergic rhinitis and urticaria. It is often described as less sedating than older antihistamines, although sleepiness remains possible. A liquid presentation may support accurate administration when a suitable measuring device and verified concentration are used. The ingredient information below is educational and is not a statement of approved pediatric indications for any Luang Pharma presentation.
Clinical context and therapeutic role
Assessment should distinguish allergy from infection and identify whether symptoms are limited to the nose, eyes or skin. An oral antihistamine can reduce itching, sneezing or hives, but it is not emergency treatment for anaphylaxis. Persistent symptoms, unexplained swelling, or a recurrent rash may require diagnosis and review of triggers. Age, renal function and other sedating medicines influence whether cetirizine is an appropriate option for an individual.
Selected safety context
Sleepiness, fatigue, headache, dry mouth and dizziness may occur. Activities requiring alertness should be avoided if affected, and alcohol or other sedating medicines can increase impairment. Kidney disease and a history of seizures warrant professional review. A liquid should not be assumed suitable for every child solely because it is a syrup. Difficulty breathing, throat swelling, collapse or a rapidly progressing allergic reaction requires emergency care rather than another antihistamine dose.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This is a proposed liquid oral presentation with a stated concentration. The liquid vehicle, sweeteners, preservatives and whether the medicine requires shaking must be verified from the final label. A liquid format does not, by itself, establish that all age groups are eligible.
Use the product’s appropriate calibrated oral measuring device and verify concentration each time a new bottle is supplied. Keep the cap and label intact. Follow the actual instructions for storage and any period after opening; do not transfer advice from another brand or concentration.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Approved/controlled formula and quantitative composition.
Approved label/leaflet with age range, indication, measuring instructions and administration directions.
Finished-product specification including container/closure and in-use/storage requirements.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: About cetirizineArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 17 February 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| FDA: warning about severe itching after stopping long-term cetirizine or levocetirizineArchived source classification: government medicine safety communication | Source revision recorded: 16 May 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-003.
Professional enquiries
Request product-specific evidence for LP-003.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.